Cibinetide, also known as ARA290 or pyroglutamic acid helix B surface peptide (pHBSP), is a synthetic oligopeptide rationally designed to selectively activate IRR24. Cibinetide interacts with the external hydrophilic domain of the EPOR/CD131 complex and has shown beneficial effects in animal models of myocardial infarction, dilated cardiomyopathy, experimental ischemic stroke, peripheral nerve injury, and wound healing. In addition, randomized placebo-controlled trials have demonstrated its safety and efficacy in human subjects with peripheral neuropathy secondary to diabetes mellitus caused by sarcoidosis or mellitus. Cibinetide improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases the abundance of small nerve fibers in the cornea.
Ara 290 Cibinetide benefits
ARA-290 is a peptide that is derived from erythropoietin (EPO). EPO has been utilized for decades because of its ability to stimulate red blood cell production within bone marrow. It can also alter a patient’s blood pressure, promote cell survival, and create a neuroprotective effect.
While ARA-290 does not stimulate red blood cell production, it does offer pain-relieving and neuroprotective effects. It also has the potential to stimulate wound repair in patients with chronic diabetes, but this property is still being researched.
More Introduction:https://iovs.arvojournals.org/article.aspx?articleid=2742767
